Detection of Bilateral Multifocal Breast Cancer Using Tc-99m Sestamibi Imaging

Derebek, Erkan; Balci, Pınar; Alanyalı, Hilmi; Koçdor, Mehmet Ali; Capa, G; Görken, İlknur Bilkay; Degirmenci, Berna; Alakavuklar, Mehmet; Canda, Tülay; Durak, Hatice

doi:10.1097/00003072-199908000-00009

Cited by 11 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radioguided surgery with 99m Tc sestamibi may be used to facilitate differentiation, similar to what is done in the parathyroid. Scintimammography with 99m Tc sestamibi has been shown to be capable of diagnosing multifocality and multicentricity in breast cancer (17,18). However, radiopharmaceutical uptake is more common in tumors larger than 1 cm or those that are palpable.…”

Section: Discussionmentioning

confidence: 99%

Radioguided Surgery Using Intravenous 99mTc Sestamibi Associated with Breast Magnetic Resonance Imaging for Guidance of Breast Cancer Resection

Duarte¹,

Santos²,

Torresan³

et al. 2006

Breast Journal

View full text Add to dashboard Cite

The purpose of this study was to evaluate the feasibility of surgery radioguided with intravenous (99m)Tc sestamibi associated with magnetic resonance imaging (MRI) of the breast to detect tumor extent and guide complete tumor resection. A descriptive experimental study was developed with 10 breast cancer patients (stage IIA-IIB) who underwent mastectomy. From 2 to 10 days before surgery, the patients underwent breast MRI with 0.1 mmol/kg of gadolinium and scintimammography with a 740 MBq of (99m)Tc sestamibi. A region of interest was drawn around the tumor image and an uptake curve as a function of time was plotted to calculate the optimal time to perform radioguided surgery. In the perioperative period, the same dose of (99m)Tc sestamibi was intravenously injected into the patients. Tumor resection was performed under the guidance of a gamma probe. MRI was used to evaluate the skin and deep fascia involvement and to detect occult tumor foci which were also excised. Subsequently a modified radical mastectomy was performed. Tumor and residual breast were histopathologically examined. In a series of 10 women, all demonstrated (99m)Tc sestamibi uptake in tumor cells. Eight patients showed no disease in the residual breast, one presented with one foci of invasive ductal carcinoma measuring 0.5 cm in diameter located 5 cm from the tumor bed, and one presented with one foci of ductal carcinoma in situ measuring 0.8 cm at the resection margin. The mean tumor size in the histopathologic assessment was 3.3 cm and in MRI was 5.0 cm. Radioguided surgery using (99m)Tc sestamibi associated with MRI is a feasible technique that can be employed in tumor resection.

show abstract

Section: Discussionmentioning

confidence: 99%

Radioguided Surgery Using Intravenous 99mTc Sestamibi Associated with Breast Magnetic Resonance Imaging for Guidance of Breast Cancer Resection

Duarte¹,

Santos²,

Torresan³

et al. 2006

Breast Journal

View full text Add to dashboard Cite

show abstract

“…E. Derebek та співавт. [84] вважають, що рання та відтермінована сцинтіграфія надають важливу додаткову інформацію при синхронному ураженні грудних залоз навіть у випадках, коли мамографія та динамічна МРМ неефективні.…”

Section: медичні наукиunclassified

Bilateral Synchronous and Metachronous Breast Cancer: Features of Topography, Etiology, Pathogenesis, Risk Factors, Diagnosis and Prognosis

Volos¹,

Masna²,

Vasyliv³

2022

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

The purpose of the study was to analyze the data of the domestic and foreign specialized literature, which are devoted to the pathogenesis, features of the topography, risk factors, prognosis of the course of bilateral synchronous and metachronous breast cancer. Materials and methods. Analytical and bibliosemantic methods were used in the research. The search for scientific information on bilateral synchronous and metachronous breast cancer for the period from 1990 to 2021 was conducted in databases of electronic searching systems. Results and discussion. Bilateral cancer can be either primary or metastatic to the contralateral breast. Primary one, depending on the time of tumor development in the contralateral breast gland, is divided into synchronous (development interval up to 6 months) and metachronous (development interval more than 6 months). Synchronous tumors of the breast glands are found significantly less frequently (22.7%) than metachronous tumors (69.6%). Relative risk factors for the occurrence of bilateral metachronous breast cancer are the presence of a BRCA1 and BRCA2 gene mutation, a heavy family history of breast cancer in blood relatives, and a young age of up to 45 years. A higher risk was established in patients with a lobular histological type of carcinoma compared to ductal carcinoma and with the absence of expression of steroid hormone receptors in the tumor. Bilateral synchronous tumors are very often characterized by the same visual manifestations during mammography, and their location in the breast glands is a "mirror image". Metachronous tumors are characterized by a smaller size, with rare involvement of axillary lymph nodes. A peculiarity of the topography of metachronous breast cancer is the presence, mainly in the upper outer quadrants of the breast gland, of a fixed or slow-moving nodule of rounded or star shape with unclear contours. Magnetic resonance mammography of the glands is an effective method of comprehensive diagnosis of breast pathology and is performed when other imaging methods are ineffective (sensitivity 99.2%, specificity 97.9%, accuracy 98.9%). The duration of the recurrence-free period in patients with synchronous tumor was 126.3 months, while in patients with metachronous tumor it was 243.7 months. Conclusion. The problem of bilateral breast cancer remains complex and far from fully understood. There are many controversial issues related to the pathogenesis, risk factors, features of the topography, clinical and morphological manifestations, diagnosis, recurrence-free and overall survival of bilateral breast carcinoma, which is important for determining and evaluating the prognosis, as well as the choice of management tactics for such patients

show abstract

“…Tc-99m sestamibi has good physical characteristics for scintimammography, and consequently high diagnostic accuracy. Moreover, this technique represents real advance in the noninvasive management of patient with early stage breast cancer [35,36].…”

Section: Reviewmentioning

confidence: 99%

Breast cancer: early diagnosis and effective treatment by drug delivery tracing

Shamsi

Islamian

2017

Nucl. Med. Rev.

View full text Add to dashboard Cite

Breast cancer is the most frequent cancer in women and it is the main reason of cancer-related deaths of women worldwide.Different types of breast cancer diagnostic examinations are also available, such as mammography, MRI, biopsy, ultrasound and molecular imaging. Radionuclide-based imaging methods including SPECT and PET are useful in early diagnosis and treatment of the cancer. The radiolabeling of chemo drugs with nanoparticles should be recommended from the standpoint of an early diagnosis and effective treatment of breast cancer.

show abstract

Detection of Bilateral Multifocal Breast Cancer Using Tc-99m Sestamibi Imaging

Abstract: This case suggests that Tc-99m sestamibi may be useful for detecting bilateral cancer, and delayed imaging may give additional information regarding the possible multifocal nature of the disease.

Cited by 11 publications

References 17 publications

Radioguided Surgery Using Intravenous 99mTc Sestamibi Associated with Breast Magnetic Resonance Imaging for Guidance of Breast Cancer Resection

Radioguided Surgery Using Intravenous 99mTc Sestamibi Associated with Breast Magnetic Resonance Imaging for Guidance of Breast Cancer Resection

Bilateral Synchronous and Metachronous Breast Cancer: Features of Topography, Etiology, Pathogenesis, Risk Factors, Diagnosis and Prognosis

Breast cancer: early diagnosis and effective treatment by drug delivery tracing

Contact Info

Product

Resources

About